Atorvia is proud to announce successful graduation of the MassBioDrive S22 program, one of only 7% of applicant companies selected to participate in the MassBio accelerator program

Read about the MassBioDrive pS22 program here 

Translating science, transforming outcomes.

Atorvia is on a journey to address major care gaps and significant medical need in acute care.

Our lead program focuses on acute kidney injury (AKI), a devastating condition which affects millions, costs billions, is often deadly -  and currently has no effective treatment available.  We are striving to become leaders in treating AKI by developing a kidney-targeted peptide that prevents regulated cell death and kidney failure, and a novel marker to detect pre-cursor AKI which we believe could become the new normal in screening for it.

A Biotech with a difference, we integrate market access & commercial strategies at all stages to transform great science into life-saving technologies that regulators will approve, payers will pay and physicians will adopt.  We believe that being unique is powerful, and this applies as much to our people are it does to our strategy so we are building a company that celebrates diversity and a culture where difference is valued.